Table 3.
Treatment-related adverse events in the included studies.
| Any grade | Grade≥3 | |
|---|---|---|
| AST increase | 148 | 61 |
| ALT increase | 116 | 27 |
| Blood bilirubin increased | 91 | 26 |
| Fatigue | 89 | 12 |
| Pruritus | 82 | 1 |
| Diarrhea | 71 | 4 |
| Decreased appetite | 66 | 4 |
| Rash | 61 | 2 |
| Asthenia | 57 | 0 |
| abdominal pain | 53 | 4 |
| AEs leading to discontinuation | 51 | 43 |
| Nausea | 44 | 2 |
| Anemia | 42 | 13 |
| Dyspnea | 33 | 1 |
| Pyrexia | 33 | 2 |
| Back pain | 29 | 4 |
| Hypothyroidism | 26 | 0 |
| Arthralgia | 25 | 1 |
| Lipase increase | 23 | 11 |
| Increased gamma-glutamyltransferase | 16 | 6 |
| Treatment-related deaths | 9 | 0 |
| Myalgia | 9 | 2 |
| Amylase increase | 9 | 2 |
| Hyperbilirubinemia | 8 | 2 |
| Adrenal insufficiency | 4 | 2 |
| Mucosal inflammation | 4 | 1 |
| Hyponatremia | 4 | 3 |
| Cardiac failure | 3 | 1 |
| autoimmune hepatitis | 3 | 2 |
| Gastric ulcer | 2 | 1 |
| Hyperlipasemia | 2 | 1 |
| Iron deficiency anemia | 2 | 1 |
| Lung infection | 2 | 1 |
| Hepatic vein thrombosis | 1 | 1 |
Some Treatment-related adverse events were not reported in some studies.
AE, adverse events; AST, aspartate aminotransferase; ALT, alanine aminotransferase.